Premium
P4‐371: Arizona Alzheimer's research registry part two progress and findings from year one
Author(s) -
Holt Connie J.,
Tariot Pierre N.,
Sabbagh Marwan,
Yaari Roy,
Jakimovich Laura,
Westlund Jennifer,
Renteria Jessica,
Thompson Kelley
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.2441
Subject(s) - telephone interview , referral , medicine , cognition , family medicine , gerontology , clinical trial , psychiatry , social science , pathology , sociology
studies. Two significant barriers exist in the development of these assays (1) the lack of experience with the performance of a novel antigen in a clinical assay, and (2) the lack of available proper human clinical samples to create reference standards and assess sample matrices. Methods: To help to overcome these obstacles, we employed a screening experimental design to assess assay optimization. Design of experiments (DOE) is a statistical tool that allows for the evaluation of all of the key assay parameters to determine the optimal conditions for the assay, as well as determine if there are any interactions of these parameters on the response of the assay. The multivariate approach that is integral to DOE helps to overcome the lack of experience with the assay reagents by facilitating an understanding of how the variables work together in the performance of the assay. Results: Here we outline the use of full and fractional factorial DOE in the optimization of a clinical assay on two platforms, Luminex® and ELISA, for the measurement of antibodies to the -amyloid peptide (A ) for a novel first-in-man vaccine program. Conclusions: Both platforms are evaluated in an attempt to determine the assay best suited to the needs of the program. We also describe the specificity experiments performed to further characterize the utility of each assay platform.